β-blockers after MI: does ABYSS confirm REDUCEd use after all?
- PMID: 39384949
- DOI: 10.1038/s41569-024-01093-z
β-blockers after MI: does ABYSS confirm REDUCEd use after all?
Conflict of interest statement
Competing interests: R.H. has received institutional lecture and advisory board fees from AstraZeneca, BMS and Pfizer. S.J. has received institutional research grants from Amgen, AstraZeneca, Jansen, Merck, Novartis and Novo Nordisk.
Comment on
-
Beta-Blocker Interruption or Continuation after Myocardial Infarction.N Engl J Med. 2024 Oct 10;391(14):1277-1286. doi: 10.1056/NEJMoa2404204. Epub 2024 Aug 30. N Engl J Med. 2024. PMID: 39213187 Clinical Trial.
References
-
- Silvain, J. et al. Beta-blocker interruption or continuation after myocardial infarction. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2404204 (2024). - DOI - PubMed
-
- Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304, 801–807 (1981).
-
- Friedman, L. M. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J. Am. Med. Assoc. 247, 1707–1714 (1982). - DOI
Publication types
LinkOut - more resources
Full Text Sources